Nanotechnology as a new strategy for the diagnosis and treatment of gliomas

Glioma is the most common malignant tumor of the central nervous system (CNS), and is characterized by high aggressiveness and a high recurrence rate.Currently, the main treatments for gliomas include surgical resection, temozolomide chemotherapy and radiotherapy.However, the prognosis of glioma patients after active standardized treatment is still poor, especially for glioblastoma (GBM); the median survival is still only 14.6 months, and the 5-year survival rate is only 4-5%.The current challenges in glioma treatment include difficulty in complete surgical resection, poor blood-brain barrier (BBB) drug permeability, therapeutic resistance, and difficulty in tumor-specific targeting.In recent years, the rapid development of nanotechnology has provided new directions for diagnosing and treating gliomas.Nanoparticles (NPs) are characterized by excellent surface tunability, precise targeting, excellent biocompatibility, and high safety.In addition, NPs can be used for gene therapy, photodynamic therapy, and antiangiogenic therapy and can be combined with biomaterials for thermotherapy.In recent decades, breakthroughs in diagnosing and treating gliomas have been made with various functional NPs, and NPs are expected to become a new strategy for glioma diagnosis and treatment.In this paper, we review the main obstacles in the treatment of glioma and discuss the potential and challenges of the latest nanotechnology in the diagnosis and treatment of glioma.